Olaparib 50 mg (Lynparza)
0.00$
Olanib, containing Olaparib as its active ingredient with the International Nonproprietary Name (INN), is primarily used to treat ovarian, breast, and pancreatic cancers. Acting as a poly (ADP-ribose) polymerase (PARP) inhibitor, Olanib disrupts cancer cell DNA repair processes, leading to their demise. The standard dosage regimen involves taking 50 mg of Olanib orally twice daily, typically with or without food. Potential side effects, including nausea, vomiting, fatigue, anemia, and diarrhea, necessitate vigilant monitoring and regular medical supervision throughout the course of treatment.
Lynparza (generic name: Olaparib) is a prescription drug for treating specific cancer types. It is part of a category of medications called PARP inhibitors (poly ADP-ribose polymerase inhibitors). One of the oral formulations available is the 50 mg version, which is generally prescribed for patients with certain genetic profiles or mutations linked to cancer progression.
What is Olaparib (Lynparza)?
Olaparib is a chemotherapy medication taken by mouth that aims to combat cancer by disrupting the ability of cancer cells to repair their DNA. The enzyme PARP assists in the repair of damaged DNA. Malignant cells, particularly those with mutations in the BRCA1 or BRCA2 genes, depend significantly on PARP for their survival. Olaparib leads to the accumulation of DNA damage in cancer cells, resulting in their death while sparing the majority of healthy cells, by inhibiting PARP.
Uses and Indications
Lynparza is mainly utilized for the treatment of these cancer types:
Ovarian Cancer: Maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to initial platinum-based chemotherapy. In patients with BRCA mutations, it is also employed in later stages of treatment.
Breast Cancer: For adults with metastatic breast cancer that is germline BRCA-mutated and HER2-negative, and who have undergone prior chemotherapy treatment.
Pancreatic Cancer: For maintenance therapy in patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not advanced after first-line treatment with platinum-based chemotherapy.
Prostate Cancer: For the treatment of metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations following previous treatment with enzalutamide or abiraterone.
The usual method for determining each patient’s eligibility for Olaparib is genetic testing to find BRCA or other homologous recombination repair (HRR) mutations.
Dosage and Administration
When it comes to side effects, interactions, or organ function considerations that necessitate dose adjustments, the typical prescription strength of Olaparib is 50 mg. The typical initial dose for adults is 300 mg two times a day, using either 100 mg or 150 mg tablets. Earlier formulations utilized the 50 mg capsules, but these have mostly been replaced by tablet forms that provide easier dosing.
Olaparib must be taken precisely as directed by a healthcare professional. Because of differences in bioavailability and formulation, capsules and tablets cannot be used interchangeably. To ensure efficacy and safety, patients must adhere to the correct version and dosage.
How to Take Olaparib 50 mg
Olaparib 50 mg (Lynparza) should be taken orally two times a day, preferably at the same time each day.
It can be taken with food, without food, or regardless of food.
Take the capsule whole without crushing, chewing, or opening it.
If you miss a dose and the usual time is less than 2 hours away, take it as soon as you can. If the delay exceeds 2 hours, omit the dose that was missed and take the next dose as scheduled.
Side Effects
Olaparib can cause side effects, as is the case with all medications. Among these, some of the more common are:
Vomiting and nausea
Exhaustion or frailty
Low red blood cell count (anemia)
Either diarrhea or constipation
Reduced appetite
Cephalalgia
Shifts in taste
Potentially severe side effects include:
myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
Pneumonitis (lung tissue inflammation)
Severe issues with bone marrow
To check for indications of these severe complications, patients are required to have routine blood tests throughout their treatment.
Drug Interactions and Precautions
Olaparib may interact with other drugs, especially those that influence the liver enzyme CYP3A4, including specific antifungals, antibiotics, and anti-seizure drugs. Be sure to notify your physician of all prescription medications, OTC products, and herbal remedies you are currently using.
In patients with liver or kidney impairment, this drug should be used carefully, and its use during pregnancy or breastfeeding is not advised because of the risk of harming the fetus.
Storage and Handling
Olaparib should be kept at a room temperature of 20°C to 25°C (68°F to 77°F).
Store the capsules in their original container, away from moisture and direct heat.
Store away from children and pets.
Conclusion
Olaparib 50 mg (Lynparza) is a major progress in the field of targeted cancer treatment, particularly for those with BRCA mutations. Due to the way it works, it can target cancer cells specifically and thus may result in longer periods of survival without disease progression. As with all cancer treatments, careful monitoring and adherence to prescribed regimens is vital for safety and effectiveness. For personalized medical advice and guidance on starting or stopping any medications, always consult your healthcare provider.
Order Now At Mdx Pharma bd….
To order from MDX Pharma BD, visit their website at https://mdxpharmabd.com, where you can browse products and place orders online. For inquiries or orders via email, contact emedicarepharma@gmail.com. Alternatively, call (+88) 01929123476. Their address is 29, Abdullahpur, Uttara, Dhaka-1230, Bangladesh.
1. What is the purpose of Olaparib (Lynparza)?
Olaparib is a targeted cancer treatment designed for specific types of cancers, such as ovarian, breast, pancreatic, and prostate cancers linked to BRCA mutations.
2. What is the mechanism of action for Olaparib?
Olaparib works as a PARP inhibitor. It functions by inhibiting the PARP enzyme, which is essential for BRCA-mutated cancer cells to mend DNA damage. PARP inhibition causes cancer cells to die.
3. Who is Olaparib 50 mg intended for?
It is prescribed for adults with certain BRCA-mutated cancers, frequently after other treatment options have been attempted. To confirm eligibility, genetic testing is usually required.
4. What is the method of administration for Olaparib 50 mg?
The 50 mg capsule is typically taken orally two times a day, with or without meals. The quantity is determined by the individualized treatment plan. Only substitute with tablets of 100 mg or 150 mg if you have been advised to do so.
5. Is it safe to take Olaparib alongside other medications?
Olaparib may interact with various medications, such as antifungals, antibiotics, and specific antidepressants. Always notify your doctor about all medications and supplements you are using.
6. Is Olaparib safe during pregnancy or breastfeeding?
No, it can harm an unborn baby and should not be used during pregnancy. It is recommended to use effective contraception during treatment and for a period afterward. While taking Olaparib, breastfeeding is also not advised.
Product Name | Olanib |
---|---|
Generic Name | Olaparib INN |
Formulation | Capsule |
Available Pack size | 112 Capsules |
Strengths | 50 mg |